George Kemble - 13 Jul 2023 Form 3 Insider Report for Sagimet Biosciences Inc. (SGMT)

Role
Director
Signature
/s/ Dennis Hom, Attorney-in-Fact
Issuer symbol
SGMT
Transactions as of
13 Jul 2023
Net transactions value
$0
Form type
3
Filing time
13 Jul 2023, 21:03:14 UTC
Next filing
20 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 5,630 $0.7900 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 3,179 $11.13 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 7,147 $23.05 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 26,352 $19.87 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 367,824 $6.36 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 46,432 $6.36 Direct F1
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 526,332 $6.36 Direct F2
holding SGMT Stock Option (Right to Buy) 13 Jul 2023 Common Stock 21,173 $7.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable as of the date hereof.
F2 The shares underlying this option vest and become exercisable in forty-eight (48) equal monthly installments following January 27, 2021, subject to the Reporting Person's continued service on each such vesting date.
F3 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney